Two years after their first official collaboration, BASF and Poietis have announced they have signed a framework agreement to further develop the field of 3D bioprinting technology.

“During our cooperation, we gained important insights… In a second step, we now want to jointly improve the skin models by increasing structure complexity and adding new cell types,” said BASF’s Sebastien Cadau.

“This agreement confirms a fruitful scientific collaboration and strengthens our partnership with the leading ingredients manufacturer for the personal care market. This is a formal recognition of Poietis’ unique technology and its valorization driven by new developments since the creation of the company,” added Bruno Brisson, Poietis Co-Founder and Vice President Business Development.